0001250853-16-000130.txt : 20160210 0001250853-16-000130.hdr.sgml : 20160210 20160210161550 ACCESSION NUMBER: 0001250853-16-000130 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 505 ITEM INFORMATION: 06c FILED AS OF DATE: 20160210 DATE AS OF CHANGE: 20160210 EFFECTIVENESS DATE: 20160210 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CYTRX CORP CENTRAL INDEX KEY: 0000799698 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 581642750 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-257215 FILM NUMBER: 161405917 BUSINESS ADDRESS: STREET 1: 11726 SAN VICENTE BOULEVARD STREET 2: SUITE 650 CITY: LOS ANGELES STATE: CA ZIP: 90049 BUSINESS PHONE: 310-826-5648 MAIL ADDRESS: STREET 1: 11726 SAN VICENTE BOULEVARD STREET 2: SUITE 650 CITY: LOS ANGELES STATE: CA ZIP: 90049 D 1 primary_doc.xml X0707 D LIVE 0000799698 CYTRX CORP 11726 SAN VICENTE BOULEVARD SUITE 650 LOS ANGELES CA CALIFORNIA 90049 310-826-5648 DELAWARE None None Corporation true Steven Kreigsman 11726 SAN VICENTE BOULEVARD SUITE 650 Los Angeles AR ARKANSAS 90049 Executive Officer Director John Caloz 11726 SAN VICENTE BOULEVARD Los Angeles CA CALIFORNIA 90049 Executive Officer Benjamin Levin 11726 SAN VICENTE BOULEVARD SUITE 650 Los Angeles CA CALIFORNIA 90049 Executive Officer d Haen 11726 SAN VICENTE BOULEVARD SUITE 650 Los Angeles CA CALIFORNIA 90049 Executive Officer Anita Chawla 11726 SAN VICENTE BOULEVARD SUITE 650 Los Angeles CA CALIFORNIA 90049 Director Louis Ignarro 11726 SAN VICENTE BOULEVARD SUITE 650 Los Angeles CA CALIFORNIA 90049 Director Joseph Rubinfeld 11726 SAN VICENTE BOULEVARD SUITE 650 Los Angeles CA CALIFORNIA 90049 Director Eric Selter 11726 SAN VICENTE BOULEVARD SUITE 650 Los Angeles CA CALIFORNIA 90049 Director Cheryl Cohen 11726 SAN VICENTE BOULEVARD SUITE 650 Los Angeles CA CALIFORNIA 90049 Director Biotechnology No Revenues 05 06c false 2016-02-05 false true false 0 1291500 1291500 0 The securities sold consisted of warrants to purchase up to 630,000 shares of the issuer's common stock at an exercise price of $2.05 per share, or a total exercise price of $1,291,500. false 2 0 true 0 0 true false CYTRX CORP /S/John Caloz John Caloz Chief Financial Officer 2016-02-10